» Articles » PMID: 8510707

Prognosis of Untreated Patients with Idiopathic Membranous Nephropathy

Overview
Journal N Engl J Med
Specialty General Medicine
Date 1993 Jul 8
PMID 8510707
Citations 122
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Defining the most appropriate treatment for patients with idiopathic membranous nephropathy is a matter of controversy. The course of the disorder is often benign, and the immunosuppressive regimens used in some patients have uncertain benefits and substantial risks. We studied the natural history of idiopathic membranous nephropathy in patients who received only symptomatic therapy.

Methods: We prospectively studied 100 consecutive patients (68 men and 32 women; mean [+/- SD] age, 51 +/- 17 years) with biopsy-proved idiopathic membranous nephropathy. The patients received diuretic or antihypertensive drugs as needed, but no glucocorticoid or immunosuppressive drugs. We examined the patients and measured their urinary protein excretion and serum creatinine concentrations every 6 months for a mean of 52 months.

Results: Twenty-four (65 percent) of the 37 patients followed for at least five years had complete or partial remission of proteinuria; in 6 others (16 percent), end-stage renal disease developed, and they required dialysis. As calculated by the Kaplan-Meier method, the estimated probability (+/- the standard error of the estimate) of retaining adequate kidney function was 88 +/- 5 percent after five years and 73 +/- 7 percent after eight years. The prognosis was poorer in men and in patients over 50 years of age, but not in patients with the nephrotic syndrome, hypertension, or hypercholesterolemia.

Conclusions: Most untreated patients with idiopathic membranous nephropathy maintain renal function for prolonged periods and are likely to have spontaneous remission. These results do not support the use of glucocorticoids and immunosuppressive drugs in patients with idiopathic membranous nephropathy.

Citing Articles

Obinutuzumab in Rituximab-resistant and recurrent membranous nephropathy: a case-series.

Sridharan K, Gopal B, Wilson S, Pham A, Hutton H J Nephrol. 2025; .

PMID: 39979558 DOI: 10.1007/s40620-025-02224-6.


Risk factors for relapse and aggravation in membranous nephropathy after COVID-19 infection.

Shu Y, Huang J, Zhang Y, Wang F, Wang X, Meng L BMC Nephrol. 2025; 26(1):71.

PMID: 39934691 PMC: 11817977. DOI: 10.1186/s12882-025-04000-x.


Pilot Trial of Hydroxychloroquine as Add-On Therapy in Patients With Membranous Nephropathy.

Yang H, Sun G, Yang X, Luan J, Jiao C, Song Q Kidney Int Rep. 2024; 9(12):3446-3454.

PMID: 39698370 PMC: 11652102. DOI: 10.1016/j.ekir.2024.09.016.


Anti Phospholipase A2 Receptor 1 Antibodies and Membranous Nephropathy Recurrence After Kidney Transplantation.

Cremoni M, Teisseyre M, Thaunat O, Fernandez C, Payre C, Moutou A Kidney Int Rep. 2024; 9(12):3427-3438.

PMID: 39698349 PMC: 11652070. DOI: 10.1016/j.ekir.2024.09.012.


Efficacy and safety of glucocorticoid combined with cyclophosphamide therapy on membranous nephropathy: a systematic review and meta-analysis.

Feng C, Chen X, Wang X, Guo M, Guo Z Front Pharmacol. 2024; 15:1480638.

PMID: 39664513 PMC: 11631627. DOI: 10.3389/fphar.2024.1480638.